Balaji Amines delivered exceptional financial performance in Q1FY27, with consolidated net profit surging 97.11% to ₹749 crore compared to ₹380 crore in the corresponding quarter of the previous year. According to the company's latest financial results, this represents one of the most significant profit growth rates in the company's recent financial history. The surge was driven by a significant expansion in EBITDA margins to 25.41% from 15.26% in the prior year period, despite a decline in sales volumes. The Board of Directors approved the unaudited standalone and consolidated financial results on July 27, 2026, with statutory auditors M/s. M. Anandam & Co. issuing limited review reports on the financial statements.
The company's consolidated revenue from operations increased 27.37% to ₹4.56 billion in Q1FY27, up from ₹3.58 billion in the same period last year. As reported in the latest financial results, this revenue growth demonstrates the company's ability to expand its market presence and operational scale during the quarter. Standalone revenue from operations was ₹429 crore, up from ₹327 crore in Q1FY26, while diluted earnings per share increased to ₹23.13 from ₹11.73 in the previous year. The company also reported cash PAT of ₹97 crore, up from ₹51 crore in Q1FY26.
EBITDA improved significantly to ₹1.16 billion from ₹547 million in Q1FY26, representing an 112.07% increase. The company demonstrated strong operational leverage, with profitability outpacing revenue growth. Standalone EBITDA margin expanded to 26% from 20%, reflecting improved cost efficiency. This margin expansion indicates enhanced operational efficiency and cost management during the quarter, with the company successfully mitigating input cost pressures through better pricing power and operational efficiencies. Total sales volumes declined to 21,587 MT in Q1FY27 from 27,570 MT in Q1FY26, indicating a strategic shift towards higher-margin products rather than volume-driven growth.
The company announced the successful commissioning of India's first commercial-scale Dimethyl Ether (DME) plant, marking a strategic entry into alternate fuel applications. The 100,000 TPA DME plant will cater to LPG blending and aerosol propellant markets, signaling the company's diversification into new product segments. Balaji Amines is also advancing its N-Methyl Morpholine (NMM) and Acetonitrile (ACN) capacity expansions during FY27. Subsidiary Balaji Speciality Chemicals Limited is executing a ₹750 crore phased expansion programme, accorded Mega Project Status by the Government of Maharashtra. Unit-I expansion for EDA-based downstream products is expected to be commissioned during FY27, while the greenfield Unit-II facility at MIDC Chincholi will produce Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN), EDTA, and EDTA-2Na, targeted for commissioning in FY27.
The disproportionate growth in profit relative to revenue highlights the effectiveness of the company's product mix optimization strategy. Total sales volumes declined to 21,587 MT from 27,570 MT in Q1FY26, indicating a strategic pivot towards higher-margin products. Amines volumes stood at 6,248.57 MT, while Amines Derivatives volumes were 8,205.11 MT, with Specialty Chemicals volumes contributing 7,132.92 MT. The sharp divergence between declining volumes and surging profitability underscores the company's successful focus on value-added specialty chemicals and derivatives. These projects aim to build indigenous capabilities in cyanide chemistry, reducing reliance on imports for pharmaceutical and agrochemical industries.
